DE69636032D1 - Plasmid zur verabreichung von nukleine säuren und verwendungsverfahren - Google Patents

Plasmid zur verabreichung von nukleine säuren und verwendungsverfahren

Info

Publication number
DE69636032D1
DE69636032D1 DE69636032T DE69636032T DE69636032D1 DE 69636032 D1 DE69636032 D1 DE 69636032D1 DE 69636032 T DE69636032 T DE 69636032T DE 69636032 T DE69636032 T DE 69636032T DE 69636032 D1 DE69636032 D1 DE 69636032D1
Authority
DE
Germany
Prior art keywords
plasmid
nucleic acids
constructs
plasmide
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69636032T
Other languages
English (en)
Other versions
DE69636032T2 (de
Inventor
M Eastman
H Durland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Urigen Pharmaceuticals Inc
Original Assignee
Urigen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Urigen Pharmaceuticals Inc filed Critical Urigen Pharmaceuticals Inc
Publication of DE69636032D1 publication Critical patent/DE69636032D1/de
Application granted granted Critical
Publication of DE69636032T2 publication Critical patent/DE69636032T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/002—Vectors comprising a special origin of replication system inducible or controllable
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/55—Vectors comprising a special origin of replication system from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/36—Vector systems having a special element relevant for transcription being a transcription termination element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/55—Vector systems having a special element relevant for transcription from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69636032T 1995-06-07 1996-04-23 Plasmid zur verabreichung von nukleine säuren und verwendungsverfahren Expired - Lifetime DE69636032T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/484,723 US5763270A (en) 1995-06-07 1995-06-07 Plasmid for delivery of nucleic acids to cells and methods of use
US484723 1995-06-07
PCT/US1996/005680 WO1996040952A1 (en) 1995-06-07 1996-04-23 Plasmid for delivery of nucleic acids to cells and methods of use

Publications (2)

Publication Number Publication Date
DE69636032D1 true DE69636032D1 (de) 2006-05-24
DE69636032T2 DE69636032T2 (de) 2006-11-23

Family

ID=23925336

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69636032T Expired - Lifetime DE69636032T2 (de) 1995-06-07 1996-04-23 Plasmid zur verabreichung von nukleine säuren und verwendungsverfahren

Country Status (9)

Country Link
US (2) US5763270A (de)
EP (1) EP0832264B1 (de)
JP (1) JP4335309B2 (de)
AT (1) ATE323169T1 (de)
AU (1) AU711187B2 (de)
CA (1) CA2222601C (de)
DE (1) DE69636032T2 (de)
PT (1) PT832264E (de)
WO (1) WO1996040952A1 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4428402A1 (de) 1994-08-11 1996-02-15 Boehringer Mannheim Gmbh Gentherapeutisches Verfahren unter Verwendung von DNA-Vektoren ohne Selektionsmarker-Gen
US5763270A (en) * 1995-06-07 1998-06-09 Genemedicine, Inc. Plasmid for delivery of nucleic acids to cells and methods of use
US6743780B1 (en) 1995-09-08 2004-06-01 Cobra Biologics Limited Plasmid stabilization
GB9518395D0 (en) * 1995-09-08 1995-11-08 Therexsys Ltd Plasmid stabilization
FR2738842B1 (fr) * 1995-09-15 1997-10-31 Rhone Poulenc Rorer Sa Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique
US20030045492A1 (en) * 1997-08-13 2003-03-06 Tang De-Chu C. Vaccination by topical application of recombinant vectors
US6348450B1 (en) * 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
US20030125278A1 (en) * 1997-08-13 2003-07-03 Tang De-Chu C. Immunization of animals by topical applications of a salmonella-based vector
US6716823B1 (en) 1997-08-13 2004-04-06 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom, and uses thereof
US6706693B1 (en) 1997-08-13 2004-03-16 The Uab Research Foundation Vaccination by topical application of genetic vectors
US6316262B1 (en) * 1997-09-19 2001-11-13 Metabolix, Inc. Biological systems for manufacture of polyhydroxyalkanoate polymers containing 4-hydroxyacids
NZ511449A (en) * 1998-12-02 2004-05-28 Univ Maryland Plasmid maintenance system for antigen delivery
US6413768B1 (en) 1998-12-02 2002-07-02 University Of Maryland Expression plasmids
US8076130B2 (en) * 1998-12-02 2011-12-13 University Of Maryland, Baltimore Plasmid maintenance system for antigen delivery
US20040009936A1 (en) * 1999-05-03 2004-01-15 Tang De-Chu C. Vaccine and drug delivery by topical application of vectors and vector extracts
US20040259252A1 (en) * 2001-07-18 2004-12-23 Sanders Mitchell C. Vector containing an enhanced p15a origin of replication
US20040235121A1 (en) * 2002-08-29 2004-11-25 Integrigen, Inc. High copy number plasmids and their derivatives
US20050026859A1 (en) * 2002-11-12 2005-02-03 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
US20080026077A1 (en) * 2002-11-12 2008-01-31 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
EP1844142B1 (de) * 2005-01-20 2015-08-12 Nature Technology Corporation Vektoren und verfahren zur genetischen immunisierung
KR20070120970A (ko) * 2005-02-23 2007-12-26 유에이비 리서치 파운데이션 알킬-글리코시드로 증진된 예방접종
WO2006099574A2 (en) * 2005-03-16 2006-09-21 Tai June Yoo Cockroach allergen gene expression and delivery systems and uses
EP1885863B1 (de) 2005-05-31 2014-11-19 The Regents of the University of Colorado, a body corporate Verfahren zur genverabreichung
JP4528972B2 (ja) * 2005-07-11 2010-08-25 国立大学法人鳥取大学 染色体組み込みマンノース発酵性ザイモモナス属細菌
CA2655990A1 (en) * 2006-06-22 2007-12-27 Tai June Yoo Restoration of hearing loss
US8247385B2 (en) * 2007-02-06 2012-08-21 Tai June Yoo Treatment and prevention of neurodegenerative diseases using gene therapy
EP2670426B1 (de) 2011-01-31 2017-05-10 The General Hospital Corporation Multimodale trail-moleküle und ihre verwendungen in zelltherapien
JP2014526882A (ja) 2011-06-21 2014-10-09 アルナイラム ファーマシューティカルズ， インコーポレイテッド 対象中の治療剤の活性を判定するアッセイおよび方法
EP2890720B1 (de) 2012-08-30 2019-07-17 The General Hospital Corporation Zusammensetzungen und verfahren zur behandlung von krebs
US20150224181A1 (en) 2012-09-14 2015-08-13 The United States Of America As Represented By The Secretary Department Of Health And Human Se Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
EP3323884A1 (de) 2013-02-01 2018-05-23 The United States Of America as Represented by the Secretary, Department of Health an Human Service Verfahren zur erzeugung von zellen im retinalen pigmentepithel aus induzierten pluripotenten stammzellen
AU2014233428B2 (en) 2013-03-15 2019-09-19 Loma Linda University Treatment of autoimmune diseases
SG10201912901YA (en) 2013-04-17 2020-02-27 Genzyme Corp Compositions and methods for treating and preventing macular degeneration
EP3848044A1 (de) 2013-05-21 2021-07-14 President and Fellows of Harvard College Manipulierte heme-bindende zusammensetzungen und verwendungen davon
SG11201606101WA (en) 2014-02-06 2016-08-30 Genzyme Corp Compositions and methods for treating and preventing macular degeneration
US20180112006A1 (en) 2015-04-17 2018-04-26 The General Hospital Corporation Agents, systems and methods for treating cancer
KR20180057610A (ko) 2015-08-03 2018-05-30 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 브라큐리 결실 돌연변이체, 브라큐리 결실 돌연변이체를 인코딩하는 비-효모 벡터, 및 이들의 용도
CA2997763A1 (en) 2015-09-08 2017-03-16 Cellular Dynamics International, Inc. Macs-based purification of stem cell-derived retinal pigment epithelium
JP6983762B2 (ja) 2015-09-08 2021-12-17 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 臨床グレードの網膜色素上皮細胞の再現性のある分化のための方法
EP3478325A4 (de) 2016-07-01 2020-01-15 Research Development Foundation Eliminierung von proliferierenden zellen aus stammzellbasierten transplantaten
EP3491134B1 (de) 2016-08-01 2023-10-11 University of Pittsburgh - of The Commonwealth System of Higher Education Menschliche induzierte pluripotente stammzellen zur hocheffizienten genmanipulation
JP7248571B2 (ja) 2016-10-05 2023-03-29 フジフィルム セルラー ダイナミクス，インコーポレイテッド ＭｅＣＰ２が破壊された誘導多能性幹細胞からの成熟系列の生成
JP7222900B2 (ja) 2016-11-09 2023-02-15 ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズ 細胞療法および創薬のための３ｄ血管化ヒト眼組織
EP3583201B1 (de) 2017-02-14 2024-01-17 University of Pittsburgh - Of the Commonwealth System of Higher Education Verfahren zur manipulation menschlicher induzierter pluripotenter stammzellen zur herstellung von lebergewebe
EP4083063A3 (de) 2017-04-18 2023-01-04 FUJIFILM Cellular Dynamics, Inc. Antigenspezifische immuneffektorzellen
CA3097428A1 (en) 2018-04-20 2019-10-24 FUJIFILM Cellular Dynamics, Inc. Method for differentiation of ocular cells and use thereof
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
CA3119041A1 (en) 2018-11-19 2020-05-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Biodegradable tissue replacement implant and its use
JP2022513652A (ja) 2018-11-28 2022-02-09 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 機能および抑制性環境に対する抵抗性を増強するための免疫細胞のマルチプレックスゲノム編集
MX2021006393A (es) 2018-11-29 2021-10-13 Univ Texas Metodos para expansion ex vivo de celulas exterminadoras naturales y uso de las mismas.
CA3180561A1 (en) 2020-05-29 2021-12-02 Andrew DIAS Bilayer of retinal pigmented epithelium and photoreceptors and use thereof
EP4157294A1 (de) 2020-05-29 2023-04-05 FUJIFILM Cellular Dynamics, Inc. Pigmentiertes retinaepithel- und photorezeptor-doppelzellaggregat und verfahren zur verwendung davon
CN117881777A (zh) 2021-05-26 2024-04-12 富士胶片细胞动力公司 防止多能干细胞中基因快速沉默的方法
CA3220602A1 (en) 2021-05-28 2022-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods to generate macular, central and peripheral retinal pigment epithelial cells
EP4346928A1 (de) 2021-05-28 2024-04-10 The United States of America, as represented by The Secretary, Department of Health and Human Services Biologisch abbaubares gewebegerüst mit sekundärmatrix zum hosten schwach adhärenter zellen
CN118159646A (zh) 2021-09-13 2024-06-07 富士胶片细胞动力公司 产生定向心脏祖细胞的方法
US20240003871A1 (en) 2022-06-29 2024-01-04 FUJIFILM Cellular Dynamics, Inc. Ipsc-derived astrocytes and methods of use thereof
US20240139256A1 (en) 2022-09-30 2024-05-02 FUJIFILM Cellular Dynamics, Inc. Methods for the production of cardiac fibroblasts

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019506A (en) * 1986-05-21 1991-05-28 University College, Cork Plasmid and uses thereof
HU197595B (en) * 1987-09-16 1989-04-28 Richter Gedeon Vegyeszet Process for producing expression vectors
US4956288A (en) * 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
DE3819463A1 (de) * 1988-06-08 1989-12-14 Behringwerke Ag Expressionsvektoren zur herstellung unfusionierter proteine in mikroorganismen
US5492890A (en) * 1990-12-03 1996-02-20 The Scripps Research Institute Polypeptides for promoting cell attachment
US5308760A (en) * 1992-01-10 1994-05-03 Washington Research Foundation Crystal proteins of Bacillus thuringiensis, genes encoding them, and host expressing them
GB9312070D0 (en) * 1993-06-11 1993-07-28 Thrombosis Res Inst Untranslated exon-1 sequences of eukaryotic genes as promoters
US5763270A (en) * 1995-06-07 1998-06-09 Genemedicine, Inc. Plasmid for delivery of nucleic acids to cells and methods of use
GB9518395D0 (en) * 1995-09-08 1995-11-08 Therexsys Ltd Plasmid stabilization

Also Published As

Publication number Publication date
EP0832264B1 (de) 2006-04-12
CA2222601C (en) 2012-07-10
AU5788096A (en) 1996-12-30
US5763270A (en) 1998-06-09
PT832264E (pt) 2006-10-31
JP4335309B2 (ja) 2009-09-30
EP0832264A1 (de) 1998-04-01
CA2222601A1 (en) 1996-12-19
ATE323169T1 (de) 2006-04-15
DE69636032T2 (de) 2006-11-23
JPH11511009A (ja) 1999-09-28
WO1996040952A1 (en) 1996-12-19
AU711187B2 (en) 1999-10-07
US6103470A (en) 2000-08-15

Similar Documents

Publication Publication Date Title
DE69636032D1 (de) Plasmid zur verabreichung von nukleine säuren und verwendungsverfahren
ZA961484B (en) Dna molecules preparation and use in gene therapy
HUP0004589A1 (hu) Javított eljárás nukleinsav bevitelére harántcsikolt izomba és kombinált alkalmazása
AU682140B2 (en) Multidrug resistance gene
HUP0004728A1 (hu) Javított eljárás nukleinsav bevitelére többsejtes eukarióta szervezet sejtjeibe és kombinált alkalmazása
CY1106216T1 (el) 5´ ESTs ΓΙΑ ΜΗ ΙΣΤΟ-ΕΙΔΙΚΕΣ ΕΚΚΡΙΤΙΚΕΣ ΠΡΩΤΕΪΝΕΣ
ATE301201T1 (de) Für die gentherapie verwendbare plasmide
MY134810A (en) Targeted gene expression of thrombopoietein, dnase i and b-interferon
WO1995024485A3 (en) Coordinate in vivo gene expression
AU2790292A (en) Viral recombinant vectors for expression in muscle cells
EP1017797A4 (de) Nicht-primaten lentivirale vektoren und verpackungssysteme
BG101103A (en) Mammalian telomerase
CY1105240T1 (el) 5’ESTs ΓΙΑ ΕΚΚΡΙΤΙΚΕΣ ΠΡΩΤΕΪΝΕΣ ΠΟΥ ΕΚΦΡΑΖΟΝΤΑΙ ΣΕ ΔΙΑΦΟΡΟΥΣ ΙΣΤΟΥΣ
DE60030324D1 (de) Replikationsunfähige herpesviren zur verwendung in gentherapie
WO1998034952A3 (en) Il-2 gene expression and delivery systems and uses
EP0848063A3 (de) Enthaltende hybride Promotoren Nukleinsäurekonstruktionen zur Verwendung in Gentherapie
ATE307886T1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
WO1999047678A3 (en) Interferon alpha plasmids and delivery systems, and methods of making and using the same
NZ504445A (en) Nucleic acid sequences of genes of the high mobility group proteins and their use in treating tumours, vascular disorders and as a contraceptive
HUP9800635A2 (hu) In vivo exogén transzfekcióra és expresszióra használható gyógyászati kombináció
WO1995034669A3 (en) Retroviral gene therapy vectors and therapeutic methods based thereon
AU6028898A (en) Methods for cultivating cells and propagating viruses
EP0763205A4 (de) Nukleinsäuresequenzen die lungenzellenspezifishe genexpression kontrollieren
HUP0100776A2 (hu) Gyulladásos sejtek önszabályzott apoptózisa génterápiával
WO2000062815A3 (en) Novel pharmaceutical composition suitable for gene therapy

Legal Events

Date Code Title Description
8364 No opposition during term of opposition